GSK slips on vaccine sales miss; cuts vaccine sales outlook
** Shares of GSK GSK.L down 2.6% at 1,502 pence; top loser on the FTSE 100 index
** Posts a 9% miss in vaccine sales after Shingrix sales missed consensus due to the U.S. demand weakness including destocking and a weaker sales outside the U.S. according to Jefferies
** Sees vaccine sales to grow by a low to mid-single digit percentage from an earlier expectation of high single-digit to low double-digit percentage growth
** Raises FY Profit and revenue outlook
** Posts Q2 adj earnings of 43.4p per share on sales of 7.88 bln pounds ($10.11 bln), above company compiled consensus
** Including session losses, stock up 3.6% YTD
($1 = 0.7792 pounds)
Reporting by DhanushVignesh Babu in Bengaluru
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.